Tuesday, October 8, 2013, 9:00 a.m. - 9:55 a.m. (Twin Peaks)
Please join us for a special presentation by BayBio in the Twin Peaks room to discuss their recently released whitepaper. This session will consist of a presentation by BayBio, followed by individual presentations by the foundations.
A Guide to Effective Patient Foundation and Life Science Industry Collaborations
By BayBio, featuring Foundation Presentations
Given declining research funds from private and public sources, avoidance of risk investment, increased R&D costs and regulatory challenges, companies and foundations share the need for fresh approaches and more efficient pathways to market. Those life science companies that can harness the power of patient groups will get to the market faster, cheaper and smarter, helping patients and rewarding investors. Though foundations bring urgency, intelligence and resources that can be essential to accelerating key steps in the drug development process, very few companies understand how to foster successful collaborations, overcome differences in their agendas and resources. To help foster more of these partnerships across the industry, BayBio recently completed the first national assessment of such collaborations -- to extract what is working well and what may lead to failure -- from a strong sample set of case studies and relationships. Through this work, BayBio provides a roadmap – both for life science companies and patient groups – of how to explore, form and navigate successful outcomes from the pioneers who led the way.
9:00 - 9:15am: Gail Maderis, President & CEO, BayBio
9:15 - 9:30am: Sharon Hesterlee, PhD, Vice President Research, Parent Project Muscular Dystrophy
9:30 - 9:45am: Michael Kelly, PhD, Chief Scientific Officer, CureDuchenne
9:45 - 10:00am: Audience Q&A
Sharon Hesterlee, PhD
Vice President Research, Parent Project Muscular Dystrophy
Dr. Hesterlee is the Vice President of Research for Parent Project Muscular Dystrophy where she oversees research investment and strategy for the organization. Previously she spent 11 years with the Muscular Dystrophy Association (MDA) where she established MDA Venture Philanthropy, designed to be a wholly-owned subsidiary exclusively focused on the discovery and commercialization of therapies for neuromuscular disease. In total, she has brokered and managed over $30M in drug development contracts with industry and other partners. Dr. Hesterlee has also been involved in the planning of numerous meetings on overcoming barriers to therapy development in rare disease.
Michael Kelly, PhD
Chief Scientific Officer, CureDuchenne
Dr. Michael Kelly joined CureDuchenne in December 2011 as chief scientific officer. Kelly, a senior pharmaceutical executive, brings more than 25 years experience in drug discovery and development to the organization. He is responsible for advancing drug development programs and identifying new drug targets that exhibit potential to transform the treatment of Duchenne muscular dystrophy.
Before joining CureDuchenne, Kelly served as president and U.S. site head of Renovis, Inc. and has held senior positions at Amgen, Inc., Wyeth (Pfizer) and Wellcome (GlaxoSmithKline).
Kelly holds a Ph.D. from the University of Southampton (U.K.), held research positions at the University of Michigan and University of Nottingham, is an inventor on more than 100 patents and is widely published in peer reviewed journals.
President & CEO, BayBio
Gail Maderis is President & CEO of BayBio, the industry organization representing and supporting Northern California’s life science community. As a former biotech CEO, Gail brings deep experience and commitment to supporting the industry through enterprise development, peer-to-peer experience sharing, advocacy and support of education and workforce development. From 2003 to 2009, Gail served as President and CEO of Five Prime Therapeutics, Inc., a privately held protein discovery and development company. At FivePrime, she successfully funded the company’s rapid growth through substantial private equity financings and corporate partnerships and took the company’s first novel cancer therapeutic from discovery into clinical trials.
Prior to FivePrime, Gail held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology. Gail practiced management and strategy consulting with Bain & Co. She serves on the boards of NovaBay Pharmaceuticals, Opexa Therapeutics, BayBio, the Mayor’s Biotech Advisory Council of San Francisco and the HBS Healthcare Initiative. Gail received a BS in business from UC Berkeley and an MBA from Harvard Business School.